What it's for (Indications)
- Gemfibrozil is primarily indicated for the treatment of severe hypertriglyceridemia (Type IV and Type V hyperlipidemia) in adult patients who are at an increased risk of pancreatitis and have not responded adequately to dietary management alone.
- This includes patients with very high serum triglyceride levels (e.
- g.
- , >500 mg/dL or 5.
- 65 mmol/L) where the primary goal is to reduce this risk.
- It is also indicated to reduce the risk of coronary heart disease (CHD) in Type IIb hyperlipoproteinemic patients without a history of CHD who have low high-density lipoprotein cholesterol (HDL-C) levels and are not responding to non-pharmacological interventions.
- The therapeutic benefits of gemfibrozil must be carefully weighed against potential risks, particularly in patients with less severe lipid abnormalities.
- Treatment initiation should always be accompanied by and maintained with a therapeutic diet and regular exercise.
- The efficacy in reducing cardiovascular morbidity and mortality in all patient populations has been established in specific clinical trials.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended adult dosage for gemfibrozil is 600 mg administered orally twice daily. To optimize absorption and efficacy, doses should be taken 30 minutes before the morning and evening meals. It is crucial that patients adhere strictly to the prescribed dietary regimen and continue engaging in appropriate physical activity during treatment. Doses exceeding 1200 mg per day are not recommended due to lack of demonstrated additional benefit and potential for increased adverse effects. In patients with mild to moderate renal impairment, caution is advised, and dose adjustments may be necessary, although gemfibrozil is generally contraindicated in severe renal dysfunction. Geriatric patients may require careful dose consideration due to potential age-related decreases in renal function and increased susceptibility to adverse events. Regular monitoring of lipid levels is essential to assess treatment response and adjust therapy as needed. |
Safety & Warnings
Common Side Effects
- Gemfibrozil, like other fibrates, can cause a range of side effects, with gastrointestinal disturbances being among the most common.
- These often include abdominal pain, dyspepsia, diarrhea, and nausea.
- Other frequently reported side effects include headache and dizziness.
- More serious, though less common, adverse events include cholelithiasis (gallstones), which can necessitate surgical intervention, due to increased cholesterol excretion into bile.
- Myopathy and rhabdomyolysis, characterized by muscle pain, tenderness, or weakness, are significant concerns, especially when gemfibrozil is co-administered with HMG-CoA reductase inhibitors (statins).
- Liver function test abnormalities (e.
- g.
- , elevated transaminases) may occur and require monitoring.
- Rare but serious hematologic effects such as anemia, leukopenia, and thrombocytopenia have been reported.
- Hypersensitivity reactions, including rash, pruritus, and urticaria, are also possible.
- Patients should be advised to report any unexplained muscle pain or tenderness immediately.
Serious Warnings
- Black Box Warning: None
- Gemfibrozil carries several important warnings and contraindications.
- It is absolutely contraindicated in patients with severe renal dysfunction, hepatic dysfunction, or pre-existing gallbladder disease due to an increased risk of complications.
- Concomitant use with statins (HMG-CoA reductase inhibitors) is generally contraindicated due to a significantly increased risk of severe myopathy and rhabdomyolysis.
- If co-administration is deemed absolutely necessary, it should be done with extreme caution and close monitoring for muscle symptoms and creatinine kinase levels.
- Gemfibrozil may potentiate the effects of oral anticoagulants (e.
- g.
- , warfarin), necessitating a reduction in anticoagulant dose and frequent monitoring of International Normalized Ratio (INR).
- Regular monitoring of liver function tests is crucial during therapy, and the drug should be discontinued if persistently elevated transaminases occur.
- Patients should be informed about the increased risk of gallstone formation.
- Its use in pregnant and lactating women is not recommended due to insufficient safety data and potential risks to the fetus or infant.
- Hypersensitivity reactions can occur, and treatment should be discontinued if such reactions develop.
- Patients with a history of hypersensitivity to gemfibrozil or any component of the formulation should avoid its use.
How it Works (Mechanism of Action)
Gemfibrozil is a fibric acid derivative that exerts its lipid-modifying effects primarily through the activation of Peroxisome Proliferator-Activated Receptor Alpha (PPAR-alpha), a nuclear receptor involved in gene regulation of lipid metabolism. Activation of PPAR-alpha by gemfibrozil leads to several key changes in lipoprotein metabolism. It significantly increases the synthesis of lipoprotein lipase (LPL), an enzyme responsible for hydrolyzing triglycerides in very low-density lipoproteins (VLDL) and chylomicrons, thereby enhancing the catabolism and clearance of triglyceride-rich lipoproteins from the circulation. Concurrently, gemfibrozil reduces the hepatic synthesis and secretion of VLDL and its apolipoprotein B component, further contributing to the reduction of plasma triglycerides. Additionally, it promotes the synthesis of apolipoproteins A-I and A-II, which are major components of high-density lipoprotein (HDL), leading to an increase in HDL-cholesterol levels. The overall effect is a substantial reduction in plasma triglyceride levels, a moderate increase in HDL-C, and often a variable, minor reduction or no change in low-density lipoprotein cholesterol (LDL-C) levels, particularly in patients with severe hypertriglyceridemia.
Commercial Brands (Alternatives)
No other brands found for this formula.